Genmab — August 2019
-
Kære venner - ingen kritik af nogen, måske bare agurketid
-
Tyndejner.. Vi opfatter det ikke som kritik. Den snakom shortning fylder bare lidt mere end vanligt
i et halvtomt ferieramt chatroom. -
Er er flertallet generelt meget tålmodige lange investorer.
-
Her er
-
Lidt om Asclepios I og II trial design: https://n.neurology.org/content/88/16_Supplement/S16.005
-
Spændende hvad der er i vente..:-)
-
Flot luk i dagens højeste.
its great, maybe the new investors pushing it up
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind